Which has better valuation and earnings, HAE or DXCM?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.07 $97.31M $2.04 44.11 DexCom $4.66B 7.18 $836.30M $2.53 35.08

Is HAE or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% DexCom 20.12% 35.94% 14.75%

Does the media favor HAE or DXCM?

In the previous week, DexCom had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for DexCom and 8 mentions for Haemonetics. DexCom's average media sentiment score of 1.26 beat Haemonetics' score of 0.97 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, HAE or HQY?

HealthEquity has higher revenue and earnings than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.07 $97.31M $2.04 44.11 HealthEquity $1.34B 6.40 $215.20M $2.67 38.33

Does the media favor HAE or HQY?

In the previous week, Haemonetics had 3 more articles in the media than HealthEquity. MarketBeat recorded 8 mentions for Haemonetics and 5 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.35 beat Haemonetics' score of 0.97 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HAE or LNTH?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.07 $97.31M $2.04 44.11 Lantheus $1.54B 4.27 $233.56M $4.14 24.37

Is HAE or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Lantheus 17.69% 28.10% 14.35%

Does the media refer more to HAE or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Haemonetics. Lantheus' average media sentiment score of 1.10 beat Haemonetics' score of 0.97 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PODD or HAE?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.58 $247.10M $5.35 26.11 Haemonetics $1.33B 3.07 $97.31M $2.04 44.11

Is PODD or HAE more profitable?

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% Haemonetics 7.12% 27.55% 9.65%

Does the media favor PODD or HAE?

In the previous week, Insulet had 29 more articles in the media than Haemonetics. MarketBeat recorded 37 mentions for Insulet and 8 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.97 beat Insulet's score of 0.37 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 6 Very Positive mention(s) 0 Positive mention(s) 30 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, QTRX or HAE?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 0.99 -$107.15M -$2.63 N/A Haemonetics $1.33B 3.07 $97.31M $2.04 44.11

Is QTRX or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -80.25% -26.09% -19.03% Haemonetics 7.12% 27.55% 9.65%

Does the media favor QTRX or HAE?

In the previous week, Quanterix had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for Quanterix and 8 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.97 beat Quanterix's score of -0.03 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Haemonetics (HAE) Competitors

$89.98 -0.82 (-0.90%)

Closing price 08/17/2026 03:58 PM Eastern

Extended Trading

$99.00 +9.02 (+10.02%)

As of 08:21 AM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? Haemonetics's main competitors and comparable companies include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Haemonetics compare to DexCom?

Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
DexCom	20.12%	35.94%	14.75%

In the previous week, DexCom had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for DexCom and 8 mentions for Haemonetics. DexCom's average media sentiment score of 1.26 beat Haemonetics' score of 0.97 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.07	$97.31M	$2.04	44.11
DexCom	$4.66B	7.18	$836.30M	$2.53	35.08

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Haemonetics currently has a consensus target price of $90.89, indicating a potential upside of 1.01%. DexCom has a consensus target price of $88.71, indicating a potential downside of 0.06%. Given Haemonetics' higher probable upside, research analysts plainly believe Haemonetics is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

DexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

Haemonetics (NYSE:HAE) and HealthEquity (NASDAQ:HQY) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 1.6% of HealthEquity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Haemonetics had 3 more articles in the media than HealthEquity. MarketBeat recorded 8 mentions for Haemonetics and 5 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.35 beat Haemonetics' score of 0.97 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HealthEquity has higher revenue and earnings than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.07	$97.31M	$2.04	44.11
HealthEquity	$1.34B	6.40	$215.20M	$2.67	38.33

HealthEquity has a net margin of 17.25% compared to Haemonetics' net margin of 7.12%. Haemonetics' return on equity of 27.55% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
HealthEquity	17.25%	14.75%	9.22%

Haemonetics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, HealthEquity has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Haemonetics currently has a consensus target price of $90.89, suggesting a potential upside of 1.01%. HealthEquity has a consensus target price of $110.93, suggesting a potential upside of 8.40%. Given HealthEquity's stronger consensus rating and higher possible upside, analysts clearly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

HealthEquity beats Haemonetics on 9 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Haemonetics (NYSE:HAE) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Lantheus had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Haemonetics. Lantheus' average media sentiment score of 1.10 beat Haemonetics' score of 0.97 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.07	$97.31M	$2.04	44.11
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.37

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.1% of Haemonetics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Haemonetics presently has a consensus target price of $90.89, suggesting a potential upside of 1.01%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.14%. Given Lantheus' higher probable upside, analysts clearly believe Lantheus is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Lantheus	17.69%	28.10%	14.35%

Haemonetics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Haemonetics on 10 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Insulet (NASDAQ:PODD) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Insulet had 29 more articles in the media than Haemonetics. MarketBeat recorded 37 mentions for Insulet and 8 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.97 beat Insulet's score of 0.37 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	6 Very Positive mention(s)	0 Positive mention(s)	30 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

99.7% of Haemonetics shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Insulet presently has a consensus price target of $195.40, suggesting a potential upside of 39.87%. Haemonetics has a consensus price target of $90.89, suggesting a potential upside of 1.01%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.58	$247.10M	$5.35	26.11
Haemonetics	$1.33B	3.07	$97.31M	$2.04	44.11

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
Haemonetics	7.12%	27.55%	9.65%

Summary

Insulet beats Haemonetics on 11 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

86.5% of Quanterix shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quanterix currently has a consensus price target of $3.00, indicating a potential upside of 2.74%. Haemonetics has a consensus price target of $90.89, indicating a potential upside of 1.01%. Given Quanterix's higher probable upside, equities analysts plainly believe Quanterix is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Haemonetics	7.12%	27.55%	9.65%

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.99	-$107.15M	-$2.63	N/A
Haemonetics	$1.33B	3.07	$97.31M	$2.04	44.11

Quanterix has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

In the previous week, Quanterix had 3 more articles in the media than Haemonetics. MarketBeat recorded 11 mentions for Quanterix and 8 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.97 beat Quanterix's score of -0.03 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Haemonetics beats Quanterix on 14 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.13B	$5.89B	$7.03B	$24.32B
Dividend Yield	N/A	1.75%	2.56%	3.69%
P/E Ratio	44.11	26.51	270.85	30.50
Price / Sales	3.07	65.17	559.55	20.14
Price / Cash	11.98	33.83	28.87	20.48
Price / Book	5.25	6.03	11.07	4.92
Net Income	$97.31M	$148.46M	$3.45B	$1.07B
7 Day Performance	3.23%	-0.26%	0.60%	0.13%
1 Month Performance	15.40%	4.26%	2.07%	2.60%
1 Year Performance	68.99%	8.11%	61.59%	18.42%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	1.9348 of 5 stars	$89.98 -0.9%	$90.89 +1.0%	+67.1%	$4.13B	$1.33B	44.11	3,009
DXCM DexCom	4.3305 of 5 stars	$87.65 +3.4%	$88.71 +1.2%	+9.6%	$31.98B	$4.66B	34.64	11,000
HQY HealthEquity	4.2053 of 5 stars	$106.79 +2.1%	$110.93 +3.9%	+13.8%	$8.75B	$1.31B	40.00	2,814	Positive News
LNTH Lantheus	3.2436 of 5 stars	$100.98 +0.0%	$108.11 +7.1%	+86.2%	$6.59B	$1.54B	24.39	1,193	Analyst Downgrade
PODD Insulet	4.8432 of 5 stars	$142.85 +1.2%	$195.40 +36.8%	-56.5%	$9.79B	$2.71B	26.70	5,400	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Is HAE or DXCM more profitable?

Does the media favor HAE or DXCM?

Which has more volatility & risk, HAE or DXCM?

Which has better valuation and earnings, HAE or DXCM?

Do insiders and institutionals hold more shares of HAE or DXCM?

Do analysts prefer HAE or DXCM?

Summary

How does Haemonetics compare to HealthEquity?

Do institutionals and insiders hold more shares of HAE or HQY?

Does the media favor HAE or HQY?

Which has higher earnings & valuation, HAE or HQY?

Is HAE or HQY more profitable?

Which has more risk & volatility, HAE or HQY?

Do analysts prefer HAE or HQY?

Summary

How does Haemonetics compare to Lantheus?

Does the media refer more to HAE or LNTH?

Which has stronger valuation and earnings, HAE or LNTH?

Do institutionals & insiders believe in HAE or LNTH?

Do analysts recommend HAE or LNTH?

Is HAE or LNTH more profitable?

Which has more risk & volatility, HAE or LNTH?

Summary

How does Haemonetics compare to Insulet?

Does the media favor PODD or HAE?

Which has more volatility & risk, PODD or HAE?

Do institutionals and insiders hold more shares of PODD or HAE?

Do analysts recommend PODD or HAE?

Which has preferable earnings & valuation, PODD or HAE?

Is PODD or HAE more profitable?

Summary

How does Haemonetics compare to Quanterix?

Do institutionals & insiders have more ownership in QTRX or HAE?

Do analysts prefer QTRX or HAE?

Is QTRX or HAE more profitable?

Which has better valuation and earnings, QTRX or HAE?

Which has more risk & volatility, QTRX or HAE?

Does the media favor QTRX or HAE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools